Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor

Viruses. 2022 Sep 13;14(9):2025. doi: 10.3390/v14092025.

Abstract

While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.

Keywords: AIDS; HIV-1; MHC-I; Nef; Nef inhibitor; antiretroviral; latent viral reservoir.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • Drug Discovery
  • HIV Infections* / drug therapy
  • HIV Seropositivity*
  • HIV-1* / physiology
  • Humans
  • Virulence Factors
  • nef Gene Products, Human Immunodeficiency Virus

Substances

  • Anti-Retroviral Agents
  • Virulence Factors
  • nef Gene Products, Human Immunodeficiency Virus
  • nef protein, Human immunodeficiency virus 1
  • nef protein, Human immunodeficiency virus 2